Skip to main content

Young Jonathan's Form 4 filing

Akero Therapeutics, Inc. (AKRO) · filed Dec 29, 2023

Accession no.
0000899243-23-020714
Filed
Dec 29, 2023
Trade date
Dec 27, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $129.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Young JonathanCIK 0001779805Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 27, 2023Common StockMOption exerciseAcquired+5,414$6.36+$34,433.04190,545Direct
Dec 27, 2023Common StockSSaleDisposed−5,414$24.00F3−$129,936185,131Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 27, 2023Common StockMOption exerciseDisposed−5,414$0.00$043,064Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.0000 to $24.0003, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)